Invitrogen Launches First Low-Cost Instruments; Portfolio Review on Track to Wrap Up This Year | GenomeWeb
Following years of speculation in the marketplace on when Invitrogen would reach beyond chemistry and service offerings and enter the instrument space, the firm this week launched the first two products in a planned series of low-cost, benchtop instruments.
 
Chairman and CEO Greg Lucier, speaking at the UBS Global Life Sciences Conference in New York this week, also said that the firm’s portfolio review, which could lead to some divestitures, is on track to be completed by the end of the year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.